Safety and immunological changes during tablet based specific immunotherapy

Grass allergen tablets (Phleum pratense, ALK-Abello A/S, Denmark) administered in a daily dose of 75,000 SQ-T before and during the grass pollen season was well-tolerated. The treatment had the ability to affect the immune system in terms of changes in specific IgE, IgG, IgA and IgX. Conclusions During period 1 (single dose), 65% of the subjects reported adverse events. Events were primarily local reactions in the throat and mouth, and were primarily mild in severity. Two events of “throat constriction” were reported in the 375,000 SQ-T group (1 severe, 1 moderate) and further dose escalation was stopped. 75,000 SQ-T was chosen as the highest dose for periods 2-4. During periods 2-4 (daily doses), 67% of the subjects reported adverse events. The most frequent were itching in mouth, eyes or throat and rhinitis. The majority was mild in severity and resolved within one day. Two participants withdrew due to adverse events, one in the 75,000 SQ-T group (sting and blisters in the mouth), and one in the placebo group (oral itching). Results